Definitive radiotherapy for squamous carcinoma of the larynx.
Definitive radiotherapy for T1 or T2 laryngeal carcinoma offers good local control and quality of voice. Recent clinical trials with hyperfractionated radiotherapy and concurrent chemoradiotherapy demonstrated improved rates of local control for advanced laryngeal cancer treated with primary radiotherapy and provides the opportunity for organ preservation. The use of amifostine and pilocarpine may prevent or ameliorate radiation-induced xerostomia. Recent advances in 3-D conformal radiotherapy and IMRT lead to a better dose distribution for sparing normal organs while treating target volumes with full dose.
Lee
Ding-Jen
DJ
Division of Radiation Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 401 North Broadway, Baltimore, MD 21231, USA. leedj@jhmi.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D018289:Carcinoma, Verrucous / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D007830:Larynx / Q000033:anatomy & histology; D009367:Neoplasm Staging; D011881:Radiotherapy, Computer-Assisted